For example, exemestane, an irreversible aromatase inhibitor, has showed an overall 65% reduction in all breast cancers and a 73% reduction specifically for ER-positive breast cancer in the intervention arm compared to the placebo group [3]. This evidence concerns the gene CYP19A1 and breast cancer.